前瞻性试验验证现有肾癌复发预测模型的局限性
该研究利用ASSURE辅助试验的前瞻性数据,在1647例切除的局部高危或局部晚期肾细胞癌患者中验证了8个复发预测模型及TNM分期。结果显示所有模型的预测能力较其原始验证明显下降,SSIGN表现最佳(C-index 0.688),UISS最差(0.556),且多数模型仅略优于TNM分期(0.60)。所有模型预测能力随时间变化,诊断后2年内最有用。
要点
- 现有肾癌复发模型在前瞻性验证中判别能力显著低于回顾性报道。
- SSIGN模型表现最佳(C-index 0.688),UISS最差(0.556)。
- 所有模型包括TNM预测能力随时间变化,诊断后2年内最有用。
核心结论
- 现有肾癌复发预测模型的前瞻性验证判别能力较其回顾性验证明显下降,临床依赖这些工具可能高估其预测能力。
- 推荐任何预测模型在用于临床实践和临床试验设计前应进行前瞻性验证。
研究设计与样本
- 利用ASSURE辅助试验(ECOG-ACRIN E2805)的前瞻性数据验证8个肾癌复发模型及TNM分期。
- 纳入1647例切除的局部高危或局部晚期肾细胞癌患者(≥pT1b grade 3/4或pTanyN1M0)。
主要发现
- 各模型预测能力较其原始及外部验证的判别估计大幅下降。
- SSIGN评分表现最佳(C-index 0.688;95% CI 0.686-0.689),UISS模型最差(0.556;95% CI 0.555-0.557)。
- 与2002 TNM分期(C-index 0.60)相比,多数模型仅略优于标准分期。
- 所有模型包括TNM的预测能力随时间有统计学显著变化,诊断后2年内最有用。
关键数值与推荐
- SSIGN评分C-index 0.688(95% CI 0.686-0.689)。
- UISS模型C-index 0.556(95% CI 0.555-0.557)。
- 2002 TNM分期C-index 0.60。
临床怎么用
- 临床医生应认识到现有回顾性预测工具可能高估预测能力,谨慎用于患者管理和临床试验筛选。
- 在临床实践和试验设计中使用任何预测模型前,应要求前瞻性验证。
局限性
- 验证人群为切除的局部高危或局部晚期肾细胞癌患者,可能限制对其他人群的推广。
- 研究未报告模型校准的具体数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To validate currently used recurrence prediction models for renal cell carcinoma (RCC) by using prospective data from the ASSURE (ECOG-ACRIN E2805; Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma) adjuvant trial. PATIENTS AND METHODS: Eight RCC recurrence models (University of California at Los Angeles Integrated Staging System [UISS]; Stage, Size, Grade, and Necrosis [SSIGN]; Leibovich; Kattan; Memorial Sloan Kettering Cancer Center [MSKCC]; Yaycioglu; Karakiewicz; and Cindolo) were selected on the basis of their use in clinical practice and clinical trial designs. These models along with the TNM staging system were validated using 1,647 patients with resected localized high-grade or locally advanced disease (≥ pT1b grade 3 and 4/pTanyN1Mo) from the ASSURE cohort. The predictive performance of the model was quantified by assessing its discriminatory and calibration abilities. RESULTS: Prospective validation of predictive and prognostic models for localized RCC showed a substantial decrease in each of the predictive abilities of the model compared with their original and externally validated discriminatory estimates. Among the models, the SSIGN score performed best (0.688; 95% CI, 0.686 to 0.689), and the UISS model performed worst (0.556; 95% CI, 0.555 to 0.557). Compared with the 2002 TNM staging system (C-index, 0.60), most models only marginally outperformed standard staging. Importantly, all models, including TNM, demonstrated statistically significant variability in their predictive ability over time and were most useful within the first 2 years after diagnosis. CONCLUSION: In RCC, as in many other solid malignancies, clinicians rely on retrospective prediction tools to guide patient care and clinical trial selection and largely overestimate their predictive abilities. We used prospective collected adjuvant trial data to validate existing RCC prediction models and demonstrate a sharp decrease in the predictive ability of all models compared with their previous retrospective validations. Accordingly, we recommend prospective validation of any predictive model before implementing it into clinical practice and clinical trial design.
引用
- Correa AF, Jegede O, Haas NB, et al. Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation. J Clin Oncol. 2019. PMID: 31216227. doi:10.1200/JCO.19.00107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。